Tim Walbert, Horizon CEO (Horizon via YouTube)

Or­phan drug spe­cial­ist Hori­zon looks to dou­ble down on its gout ex­per­tise with ac­quired rights to Ar­row­head­'s RNAi med

Hori­zon Ther­a­peu­tics has made a name for tak­ing or­phan drugs once left on the scrap heap and spin­ning them in­to ap­proved ther­a­pies. Along the way, the biotech has picked up an ex­per­tise in gout with best­selling Krys­texxa, and now it’s look­ing to dou­ble down in that space with a li­cens­ing deal for an Ar­row­head drug.

Hori­zon will pay $40 mil­lion up­front for glob­al rights to Ar­row­head Phar­ma­ceu­ti­cals’ ARO-XDH, an in­ves­ti­ga­tion­al RNAi ther­a­py for un­con­trolled gout, the part­ners said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.